Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial.
Laurent Mortier, Émilie Le Rhun(University of Zurich), X. Mirabel(American Society of Clinical Oncology), Célèste Lebbé(Inserm), Thierry Lesimple, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), L. Machet(Université de Tours), Nicolas Reyns(Inserm), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), Jean‐Jacques Grob(Aix-Marseille Université), C. Templier, L. Thomas(University of Liverpool), E. Desmedt(Université de Lille), Philippe Jamme(Inserm), Caroline Robert(Institut Gustave Roussy), Alain Duhamel(Université de Lille)
Cited by 4
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k